Physician profile
Marisa Stringer
NPI 1043327034
$68,339.33
in general payments reported to CMS, 2019-2025
23 companies · $13K in 2025
The $13K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11K · 2022: $19K · 2023: $15K · 2024: $10K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Travel and Lodging: $7,399 · Food and Beverage: $5,567 · Consulting Fee: $2,152 · Education: $236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,755.00 |
| Travel and Lodging | $7,398.73 |
| Food and Beverage | $5,567.09 |
| Consulting Fee | $2,151.50 |
| Education | $236.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $32,422.50 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $30,833.65 | 2021-2025 | Dupixent |
| Incyte Corporation | $1,248.15 | 2021-2025 | Opzelura |
| Abbvie INC. | $960.08 | 2021-2025 | |
| Galderma Laboratories, L.P. | $504.47 | 2022-2025 | Nemluvio, Dysport, Aklief |
| Novartis Pharmaceuticals Corporation | $467.54 | 2021-2025 | |
| Allergan, INC. | $373.31 | 2021-2022 | |
| Leo Pharma INC. | $258.02 | 2021-2025 | Anzupgo, Adbry, Spevigo |
| Sun Pharmaceutical Industries INC. | $205.87 | 2021-2025 | |
| Pfizer INC. | $194.20 | 2021-2025 | |
| Janssen Biotech, INC. | $193.93 | 2021-2025 | Tremfya |
| Revance Therapeutics, INC. | $103.65 | 2024 | Daxxify |
| Ucb, INC. | $96.05 | 2021-2025 | Bimzelx |
| Lilly USA, LLC | $68.33 | 2021-2025 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $66.73 | 2025 | Sotyktu |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $66.12 | 2022-2025 | Otezla |
| Organon LLC | $64.03 | 2025 | Vtama |
| Almirall LLC | $58.77 | 2025 | Seysara, Klisyri |
| Botanix Sb INC | $43.35 | 2025 | Sofdra |
| Mayne Pharma Commercial LLC | $34.25 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $29.00 | 2021 | |
| Boston Scientific Corporation | $28.32 | 2022 | |
| Dermavant Sciences, INC. | $19.01 | 2023 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marisa Stringer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.